top of page

How CD4+ T cells respond to SARS-CoV-2 in COVID-19 recovered patients

An international team of researchers from the Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, has deciphered the T cell responses occurring during COVID-19 infection at single-cell resolution. This study, which was performed at the Center of Medical Immunology under the leadership of Prof. Federica Sallusto, included collaborations with clinical institutions from Ticino and Italy: Ente Ospedaliero Cantonale (EOC), the Clinica Luganese Moncucco, the Policlinico S. Matteo in Pavia, and INGM Milano, is published in the current issue of Science.

T lymphocytes are a subset of immune cells in the blood that mount a protective immune response against foreign pathogens such as SARS-CoV-2. These T lymphocytes can directly neutralize the threat and/or indirectly help by promoting antibody production. "A precise understanding of how T cells respond to SARS-CoV-2 infection could help inform the design of next generation vaccines to coronaviruses," says Prof. Federica Sallusto.

The SARS-CoV-2 virus is composed of several proteins, including the Spike glycoprotein, which contains a domain that latches onto host cells for infection, called the receptor-binding-domain (RBD). "We wanted to understand which SARS-CoV-2 proteins are highly targeted by CD4+ T cells, a T cell type that helps the immune response to fight against infectious pathogens," says Dr. Federico Mele, a main author of this study. By profiling almost 3000 CD4+ T cells isolated from 34 SARS-CoV-2-exposed donors, the team found that the RBD is highly targeted. "Strikingly, a 20-amino-acid stretch of the RBD is recognized by almost all donors. The discovery of this immunodominant region highlights a shared molecular basis of immune recognition in all individuals exposed to SARS-CoV-2 infection or vaccination," says Daniela Vaqueirinho, a USI doctoral student and another main author of the study.

Read more at:

3 views0 comments


Post: Blog2_Post
bottom of page